| Literature DB >> 33061961 |
Kwangil Yim1, Jung Ha Shin2, Jinyoung Yoo3.
Abstract
METHODS: In total, 123 IND cases with final diagnoses of cancer (29.3%), high-grade dysplasia (6.5%), low-grade dysplasia (11.4%), and nonneoplasm (52.8%) were randomly divided into test set (n = 27) and validation set (n = 96). By the image analysis, size, pleomorphism, hyperchromasia, irregularity of nuclei, and ratios of structural atypia area (SAA) to total IND area were measured in the test set. Using the validation set, consensus meetings were held for the evaluation of pathologic factors that predict the final diagnosis.Entities:
Year: 2020 PMID: 33061961 PMCID: PMC7542492 DOI: 10.1155/2020/9460681
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Representative images of structural atypia area (red-lined inner area) and area with total indefinite for dysplasia (black-lined inner area) In the red-lined inner area, one or more of the following are seen: variable glandular size, irregular glandular arrangement, glandular branching/budding, and glandular cribriform. In the black-lined inner area, one or more of structural or nuclear atypia are visible. (a) Structural atypia was present in 6.18% of the area, with a final diagnosis of nonneoplasm (hematoxylin and eosin; ×40 magnification). (b) The area ratio of the structural atypia was 61.1%, with a final diagnosis of carcinoma (hematoxylin and eosin; ×40 magnification). (c) A representative image of an area of nuclear atypia without structural atypia. Loss of surface maturation (arrow), nuclear enlargements, and hyperchromasia are visible (hematoxylin and eosin; ×100 magnification). (d) A representative image of an area of structural atypia. Glandular variation in size, irregular arrangement, and branching/budding (arrow) are visible (hematoxylin and eosin; ×200 magnification).
Figure 2Flow chart of study inclusion and exclusion criteria and enrolment of 123 lesions with indefinite for dysplasia. ER: endoscopic resection; HGD: high-grade dysplasia; IND: indefinite for dysplasia; LGD: low-grade dysplasia.
The diagnostic delays and clinicopathological correlation.
| Early <2 weeks ( | Delayed ≥2 weeks ( |
| Early <2 months ( | Delayed ≥2 months ( |
| Early <6 months ( | Delayed ≥6 months ( |
| Early <1 year ( | Delayed ≥1 year ( |
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Repeated IND/negative in 2nd biopsy | ||||||||||||
| No | 13 | 102 | 0.598 | 43 | 72 | 0.257 | 78 | 37 | 0.021 | 93 | 22 | 0.013 |
| Yes | 0 | 8 | 1 | 7 | 2 | 6 | 3 | 5 | ||||
| Stage | ||||||||||||
| ≤pT1a | 11 | 103 | 0.242 | 39 | 75 | 0.279 | 75 | 39 | 0.718 | 90 | 24 | 0.41 |
| ≥pT1b | 2 | 7 | 5 | 4 | 5 | 4 | 6 | 3 |
IND: indefinite for dysplasia.
Clinical and endoscopic features according to final diagnosis.
| Nonneoplasm ( | Neoplasm ( |
| Noncarcinoma ( | Carcinoma ( |
| |
|---|---|---|---|---|---|---|
| Age (years old) | 64.8 ± 12.2 | 67.8 ± 8.97 | 0.126 | 65.2 ± 11.5 | 68.8 ± 8.64 | 0.092 |
| Sex | ||||||
| Male | 49 | 40 | 0.427 | 63 | 26 | 0.574 |
| Female | 16 | 18 | 24 | 10 | ||
| Endoscopic findings | ||||||
| Mean size (mm) | 3.00 ± 2.66 | 2.86 ± 2.09 | 0.752 | 3.00 ± 2.62 | 2.78 ± 1.79 | 0.465 |
| <4 mm | 59 | 51 | 0.09 | 78 | 32 | 0.09 |
| ≥4 mm and <10 mm | 2 | 5 | 4 | 3 | ||
| ≥10 mm | 4 | 2 | 5 | 1 | ||
| Location | ||||||
| Lower third | 41 | 31 | 0.09 | 50 | 22 | 0.094 |
| Mid third | 22 | 25 | 35 | 12 | ||
| Upper third | 2 | 2 | 2 | 2 | ||
| Gross type | ||||||
| Type I | 3 | 8 | 0.09 | 4 | 7 | 0.101 |
| Type IIa | 8 | 4 | 10 | 2 | ||
| Type IIb | 9 | 11 | 14 | 6 | ||
| Type IIc | 41 | 29 | 54 | 16 | ||
| Type III | 4 | 6 | 5 | 5 | ||
| Number of biopsies | 2.02 ± 1.42 | 2.17 ± 1.48 | 0.549 | 1.98 ± 1.27 | 2.36 ± 1.79 | 0.18 |
Data are presented number or mean with standard deviation (mm).
The Results of image analysis for pathologic factors associated with nuclear and structural atypia.
| Nonneoplasm | Neoplasm |
| Below LGD | Above HGD |
| Noncarcinoma | Carcinoma |
| ||
|---|---|---|---|---|---|---|---|---|---|---|
| ( | ( | ( | ( | ( | ( | |||||
| Nuclear | Size ( | 16.3 ± 3.4 | 18.6 ± 5.0 | 0.186 | 16.3 ± 3.3 | 18.7 ± 5.1 | 0.156 | 16.6 ± 3.3 | 18.6 ± 5.3 | 0.237 |
| Pleomorphism ( | 5.6 ± 2.1 | 5.5 ± 1.7 | 0.806 | 5.5 ± 2.0 | 5.6 ± 1.7 | 0.895 | 5.6 ± 2.0 | 5.5 ± 1.8 | 0.957 | |
| Hyperchromasia (%) | 79.8 ± 8.0 | 81.0 ± 7.9 | 0.689 | 79.4 ± 7.9 | 81.6 ± 7.9 | 0.48 | 79.0 ± 7.7 | 82.2 ± 7.9 | 0.302 | |
| Irregularity ( | 3.0 ± 0.29 | 3.2 ± 0.4 | 0.137 | 3.0 ± 0.29 | 3.2 ± 0.41 | 0.969 | 3.0 ± 0.31 | 3.2 ± 0.42 | 0.294 | |
| Structure | Area ratio (%) | 15.1 ± 16.4 | 46.4 ± 17.3 | <0.001 | 15.0 ± 15.7 | 48.9 ± 15.1 | <0.001 | 15.7 ± 15.4 | 50.8 ± 14.0 | <0.001 |
Data are presented mean with standard deviation (%, μm and μm2). LGD: low-grade dysplasia; HGD: high-grade dysplasia.
Figure 3Sum of the sensitivity and specificity for predicting final diagnoses according to area ratio with structural atypia to total indefinite for dysplasia by plotting receiver operating characteristic curves. Cut-off values were defined as 25.3% for neoplasm, 25.3% for above high-grade dysplasia, and 26.1% for carcinoma.
Interpretation of results of pathologic factors for predicting carcinoma by two pathologists.
| Pathologist1 | Pathologist2 | Cohen's Kappa coefficients | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Noncarcinoma ( | Carcinoma ( |
| Noncarcinoma ( | Carcinoma ( |
| ||||
| Effectible factors | Neutrophils | ≤mild | 34 | 10 | 0.408 | 1 | 0 | 0.75 | 0.959 |
| ≥moderate | 38 | 14 | 74 | 24 | |||||
| Ulcer | Absent | 41 | 17 | 0.168 | 43 | 17 | 0.234 | 0.956 | |
| Present | 31 | 7 | 29 | 7 | |||||
| Intestinal metaplasia | <50% | 65 | 24 | 0.124 | 68 | 24 | 0.31 | 0.712 | |
| ≥50% | 7 | 0 | 4 | 0 | |||||
|
| |||||||||
| Structural atypia | Loss of surface maturation | Absent | 37 | 3 | 0.001 | 42 | 7 | 0.012 | 0.813 |
| Present | 35 | 21 | 30 | 17 | |||||
| Margination | Absent | 61 | 19 | 0.364 | 62 | 19 | 0.304 | 0.731 | |
| Present | 11 | 5 | 10 | 5 | |||||
| Cribriform | Absent | 58 | 9 | <0.001 | 65 | 14 | 0.001 | 0.664 | |
| Present | 14 | 15 | 7 | 10 | |||||
| Branching/budding | Absent | 67 | 13 | <0.001 | 70 | 17 | 0.001 | 0.682 | |
| Present | 5 | 11 | 2 | 7 | |||||
| Arrangement | Regular | 40 | 3 | <0.001 | 44 | 6 | 0.002 | 0.855 | |
| Irregular | 32 | 21 | 28 | 18 | |||||
| Crowding | Absent | 43 | 5 | 0.001 | 45 | 11 | 0.116 | 0.833 | |
| Present | 29 | 19 | 27 | 13 | |||||
| SAA > 25% | No | 56 | 5 | <0.001 | 55 | 4 | <0.001 | 0.956 | |
| Yes | 16 | 19 | 17 | 20 | |||||
|
| |||||||||
| Nuclear atypia | Loss of nuclear polarity | Absent | 48 | 8 | 0.004 | 51 | 11 | 0.026 | 0.869 |
| Present | 24 | 16 | 21 | 13 | |||||
| Pseudostratification | <half | 39 | 7 | 0.029 | 43 | 13 | 0.403 | 0.793 | |
| ≥half | 33 | 24 | 29 | 11 | |||||
| Pleomorphism | Absent | 65 | 20 | 0.279 | 67 | 21 | 0.318 | 0.825 | |
| Present | 7 | 4 | 5 | 3 | |||||
| Hyperchromasia or vesicular | Absent | 2 | 0 | 0.561 | 4 | 2 | 0.469 | 0.484 | |
| Present | 70 | 24 | 68 | 22 | |||||
| Prominent nucleoli | Absent | 20 | 3 | 0.104 | 23 | 6 | 0.356 | 0.843 | |
| Present | 52 | 21 | 49 | 18 | |||||
SAA: structural atypia area.
Figure 4Multivariate analysis of pathologic factors for predicting final diagnosis. Data for the difference in area under the curve are summarized in Table 5.
Multivariate analysis of pathologic factors for predicting final diagnosis.
| Predicting neoplasm | Predicting above HGD | Predicting carcinoma | |||||
|---|---|---|---|---|---|---|---|
| Pathologist1 | Pathologist2 | Pathologist1 | Pathologist2 | Pathologist1 | Pathologist2 | ||
| dAUC | dAUC | dAUC | dAUC | dAUC | dAUC | ||
| Structural atypia | Loss of surface maturation | 0.074 | 0.083 | 0.098 | 0.083 | 0.081 | 0.090 |
| Margination | 0.012 | 0.019 | 0.000 | 0.019 | 0.013 | 0.000 | |
| Cribriform | 0.041 | 0.051 | 0.074 | 0.051 | 0.103 | 0.113 | |
| Branching/budding | 0.050 | 0.073 | 0.066 | 0.073 | 0.095 | 0.086 | |
| Arrangement | 0.027 | 0.038 | 0.094 | 0.038 | 0.115 | 0.102 | |
| Crowding | 0.021 | 0.065 | 0.039 | 0.065 | 0.042 | 0.095 | |
| SAA > 25% | 0.130 | 0.110 | 0.173 | 0.110 | 0.182 | 0.135 | |
|
| |||||||
| Nuclear atypia | Loss of nuclear polarity | 0.007 | 0.024 | 0.064 | 0.024 | 0.080 | 0.083 |
| Pseudostratification | −0.036 | 0.019 | 0.027 | 0.019 | 0.005 | 0.057 | |
| Pleomorphism | −0.068 | −0.030 | −0.079 | −0.030 | −0.016 | 0.010 | |
| Hyperchromasia | −0.062 | −0.016 | −0.088 | −0.016 | −0.047 | 0.000 | |
| Prominent nucleoli | −0.095 | −0.036 | −0.068 | −0.036 | 0.002 | 0.041 | |
dAUC: differences in area under curve; HGD: high-grade dysplasia; SAA: structural atypia area.
Criteria for risk stratification of indefinite for dysplasia and malignancy rates.
| SAA > 25% | Loss of surface maturation | Category | Malignancy rate |
|---|---|---|---|
| No | None of the above | 0 | 0% |
| ≥1 of the above | 1 | 15.2–16.7% | |
| Yes | None of the above | 2 | 44.4–50.0% |
| ≥1 of the above | 3 | 54.5–55.6% |
SAA: structural atypia area.